Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Common Equity (2023 - 2025)

CG Oncology filings provide 3 years of Common Equity readings, the most recent being $752.6 million for Q4 2025.

  • On a quarterly basis, Common Equity rose 2.62% to $752.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $752.6 million, a 2.62% increase, with the full-year FY2025 number at $752.6 million, up 2.62% from a year prior.
  • Common Equity hit $752.6 million in Q4 2025 for CG Oncology, up from $687.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $752.6 million in Q4 2025 to a low of -$123.1 million in Q4 2023.
  • Median Common Equity over the past 3 years was $560.6 million (2024), compared with a mean of $399.4 million.
  • Biggest five-year swings in Common Equity: soared 760.66% in 2024 and later rose 2.62% in 2025.
  • CG Oncology's Common Equity stood at -$123.1 million in 2023, then surged by 695.76% to $733.4 million in 2024, then increased by 2.62% to $752.6 million in 2025.
  • The last three reported values for Common Equity were $752.6 million (Q4 2025), $687.6 million (Q3 2025), and $670.4 million (Q2 2025) per Business Quant data.